AEON News

AEON Biopharma, a Phase 2 biotech developing a botulinum toxin therapy for neuro and gastroenterology indications, withdrew its plans for an initial public offering on Wednesday. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16, but postponed ahead of pricing in October.  The Newport Beach, CA-based company was founded in 2012 and...read more

AEON Biopharma, a Phase 2 biotech developing a botulinum toxin therapy for neuro and gastroenterology indications, postponed its IPO on Friday. It had filed to raise $75 million by offering 5 million shares at a price range of $14 to $16. AEON is developing its proprietary botulinum toxin complex, ABP-450 (prabotulinumtoxinA), for debilitating medical conditions, with an initial...read more

AEON Biopharma, a Phase 2 biotech developing a botulinum toxin therapy for neuro and gastroenterology indications, announced terms for its IPO on Monday. The Newport Beach, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint of the proposed range, AEON Biopharma would command a fully diluted market value of $331...read more

The IPO market was full steam ahead this past week as 11 IPOs came to market. SPAC activity remained steady with seven blank check IPOs. New filers continue to pour into the IPO pipeline, with 15 IPOs and eight SPACs submitting initial filings. Tech consultancy Thoughtworks (TWKS) raised $774 million at a $7.0 billion market cap. This agile software developer...read more